Literature DB >> 12963832

Polo-like kinase 1 in the life and death of cancer cells.

Xiaoqi Liu1, Raymond L Erikson.   

Abstract

The polo-like kinase family plays a vital role in many cell cycle related events. The family includes mammalian Plkl, Snk (Plk2), and Fnk/Prk (Plk3), Xenopus laevis Plxl,Drosophila polo, fission yeast Plol, and budding yeast Cdc5. These enzymes, in addition to a conserved kinase domain at the N-terminus, have highly conserved sequences called polo-box(s) in the non-catalytic C-terminal domain. Genetic and biochemical experiments with several different organisms have documented that polo-like kinases are involved in many aspects of the cell cycle, such as activation of Cdc2, centrosome assembly and maturation, activation of the anaphase-promoting complex (APC) during the metaphase-anaphase transition, and cytokinesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963832

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  Polo-like kinase 2 regulates angiogenic sprouting and blood vessel development.

Authors:  Hongbo Yang; Longhou Fang; Rui Zhan; Jeffrey M Hegarty; Jie Ren; Tzung K Hsiai; Joseph G Gleeson; Yury I Miller; JoAnn Trejo; Neil C Chi
Journal:  Dev Biol       Date:  2015-05-22       Impact factor: 3.582

2.  Involvement of polo-like kinase 1 (Plk1) in mitotic arrest by inhibition of mitogen-activated protein kinase-extracellular signal-regulated kinase-ribosomal S6 kinase 1 (MEK-ERK-RSK1) cascade.

Authors:  Ran Li; Dian-Fu Chen; Rong Zhou; Sheng-Nan Jia; Jin-Shu Yang; James S Clegg; Wei-Jun Yang
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

3.  Identifying radiation exposure biomarkers from mouse blood transcriptome.

Authors:  Daniel R Hyduke; Evagelia C Laiakis; Heng-Hong Li; Albert J Fornace
Journal:  Int J Bioinform Res Appl       Date:  2013

4.  Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.

Authors:  Feng-Feng Xie; Shi-Shi Pan; Rong-Ying Ou; Zhen-Zhen Zheng; Xiao-Xiu Huang; Meng-Ting Jian; Jian-Ge Qiu; Wen-Ji Zhang; Qi-Wei Jiang; Yang Yang; Wen-Feng Li; Zhi Shi; Xiao-Jian Yan
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

5.  RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.

Authors:  C Yu; X Zhang; G Sun; X Guo; H Li; Y You; J L Jacobs; K Gardner; D Yuan; Z Xu; Q Du; C Dai; Z Qian; K Jiang; Y Zhu; Q Q Li; Y Miao
Journal:  J Cell Mol Med       Date:  2008-02-05       Impact factor: 5.310

6.  Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel.

Authors:  Fa Liu; Jung-Eun Park; Wen-Jian Qian; Dan Lim; Martin Gräber; Thorsten Berg; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Nat Chem Biol       Date:  2011-07-17       Impact factor: 15.040

7.  Synthesis of an anthraquinone derivative (DHAQC) and its effect on induction of G2/M arrest and apoptosis in breast cancer MCF-7 cell line.

Authors:  SweeKeong Yeap; Muhammad Nadeem Akhtar; Kian Lam Lim; Nadiah Abu; Wan Yong Ho; Seema Zareen; Kiarash Roohani; Huynh Ky; Sheau Wei Tan; Nordin Lajis; Noorjahan Banu Alitheen
Journal:  Drug Des Devel Ther       Date:  2015-02-17       Impact factor: 4.162

Review 8.  Suppressive Effects of EGCG on Cervical Cancer.

Authors:  Ying-Qi Wang; Jian-Liang Lu; Yue-Rong Liang; Qing-Sheng Li
Journal:  Molecules       Date:  2018-09-12       Impact factor: 4.411

9.  Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.

Authors:  Monika Raab; Mourad Sanhaji; Shengtao Zhou; Franz Rödel; Ahmed El-Balat; Sven Becker; Klaus Strebhardt
Journal:  Neoplasia       Date:  2019-03-07       Impact factor: 5.715

10.  Plx1 is required for chromosomal DNA replication under stressful conditions.

Authors:  Kristina Trenz; Alessia Errico; Vincenzo Costanzo
Journal:  EMBO J       Date:  2008-02-28       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.